Lu Zhang

Lu Zhang is a Principal Scientist at Roche Shanghai, where they currently contribute to advancing scientific research. They previously held roles as an Associate Director at BeiGene and a Senior Scientist at TCRCure Biopharma Corp., where they initiated and developed the TURBO-T platform to enhance adoptive T cell therapy. Lu also served as a Postdoctoral Research Associate at Duke University, where they identified key factors affecting islet cell activity and developed innovative screening platforms. Lu earned a Ph.D. in Immunology from the University of North Carolina at Chapel Hill.